Overall Status

Recruiting (3)

Not yet recruiting (1)

Phase

phase 1 (1)

phase 1/phase 2 (1)

Sponsor

City of Hope Medical Center (1)

Curis, Inc. (1)

Princess Maxima Center for Pediatric Oncology (1)

St. Jude Children's Research Hospital (1)

Collaborator

National Cancer Institute (NCI) (1)

Intervention

acetaminophen (1)

advice (1)

dexamethasone (1)

diphenhydramine (1)

emavusertib (1)

flotetuzumab (1)

ibrutinib (1)

ibuprofen (1)

ranitidine (1)

Study Documents

Intervention Type

drug (2)

biological (1)

other (1)

Funder Type

Other (3)

Industry (1)

Study Type

Interventional (2)

Observational (2)

refractory hematologic malignancy

Showing 1 - 4 of 4

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

After Adoptive Transfer of Genetically Modified Cell Products

Recruiting

Relapsed Hematologic Malignancy
Refractory Hematologic Malignancy

Memphis, Tennessee

St. Jude Children's Research Hospital

Feb 6, 2023

Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy Trial in United States (Emavusertib, ibrutinib)

Recruiting

Relapsed Hematologic Malignancy
Refractory Hematologic Malignancy

Phoenix, Arizona
+10 more

Feb 1, 2023

Recurrent Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Blastic Plasmacytoid Dendritic Cell Tumor Trial in

Recruiting

Recurrent Acute Leukemia
+16 more

Acetaminophen
+5 more

Duarte, California

City of Hope Medical Center

Nov 22, 2022

International Leukemia Target Board

Not yet recruiting

Relapsed Hematologic Malignancy
Refractory Hematologic Malignancy

Advice

(no location specified)

Feb 25, 2022